---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211850"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:39:21.326881+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer

## Summary
- Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.
- Cash, equivalents & short-term investments $233.2M; includes ~$21M net from ATM at $10.00/share.
- Full-year 2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45k, net loss ~$105M.
- Second Medicare coverage in six months (lung cancer surveillance) follows prior breast cancer win.
- CEO states 'Win-in-MRD' strategy working; clinical revenue expected to grow five-fold in 2026.

## SEC filing metadata
- accession: 0001193125-26-211850
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526211850/0001193125-26-211850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526211850/psnl-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211850
- JSON: https://secwatch.observer/filing/0001193125-26-211850.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211850.txt

## Source-grounded claims
- claim_id: b4caa30d54f086cb4260d0e53e54aa5df70093f2
  claim: Personalis, Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
  evidence_excerpt: On May 7, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000119312526211850/0001193125-26-211850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.